Long-term outcome of branched-chain amino acid treatment in patients with liver cirrhosis

Hepatology Research

Volumn 38, Issue SUPPL. 1, 2008, Pages

  Moriwaki, Hisataka ^a   Shiraki, Makoto ^a   Fukushima, Hideki ^a   Shimizu, Masahito ^a   Iwasa, Junpei ^a   Naiki, Takafumi ^a   Nagaki, Masahito ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Branched chain amino acids (BCAA); Liver cancer; Liver cirrhosis; Liver failure; Obesity; Survival

Indexed keywords

BRANCHED CHAIN AMINO ACID;

ASCITES; BODY MASS; CANCER RISK; CLINICAL TRIAL; CONFERENCE PAPER; DEATH; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; ESOPHAGUS VARICES; EUROPE; HEALTH CARE ORGANIZATION; HEPATIC ENCEPHALOPATHY; HUMAN; INCIDENCE; ITALY; JAPAN; JAUNDICE; LIPID STORAGE; LIVER CANCER; LIVER CIRRHOSIS; LIVER FAILURE; LONGITUDINAL STUDY; NUTRITIONAL SUPPORT; OBESITY; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN CALORIE MALNUTRITION; QUALITY OF LIFE; SHORT FORM 36; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 58049108771     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00434.x     Document Type: Conference Paper

References (24)

1. Alberino F, Gatta A, Amodio P et al. Nutrition and survival in patients with liver cirrhosis. Nutrition 2001; 17: 445-50.
2. Tajika M, Kato M, Mohri H et al. Prognostic value of energy metabolism in patients with liver cirrhosis. Nutrition 2002; 18: 229-34.
3. Plauth M, Cabre E, Riggio O et al. ESPEN guidelines on enteral nutrition: Liver disease. Clin Nutr 2006; 25: 285-94.
4. ASPEN Board of Directors and the Clinical Guidelines Task Force. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN 2002; 26 (Suppl 1): 73-6.
5. Yoshida T, Muto Y, Moriwaki H, Yamato M. Effect of long-term oral supplementation with branched-chain amino acid granules on the prognosis of liver cirrhosis. J Gastroenterol 1989; 24: 692-8.
6. Charlton M. Branched-chain amino acid-enriched supplements as therapy for liver disease: Rasputin lives. Gastroenterology 2003; 124: 1980-2.
7. Marchesini G, Bianci G, Merli M et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: A double-blind, randomized trial. Gastroenterology 2003; 124: 1792-801.
8. Poon RTP, Yu WC, Fan ST et al. Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: A randomized trial. Aliment Pharmacol Ther 2004; 19: 779-88.
9. Muto Y, Sato S, Watanabe A et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005; 3: 705-13.
10. Nakaya Y, Okita K, Suzuki K et al. BCAA-enriched snack improves nutritional state of cirrhosis. Nutrition 2007; 23: 113-20.
11. Sanyal AG, Koff RS. Methodologies in outcomes research. Hepatology 1999; 29: 1S-2S.
12. Muto Y, Sato S, Watanabe A et al. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 2006; 35: 204-14.
13. El-Serag HB. Hepatocellular carcinoma: Trends in the United States. Gastroenterology 2004; 127 (Suppl 1): S27-34.
14. Kiyosawa K, Umemura T, Ichijo T et al. Hepatocellular carcinoma: Recent trends in Japan. Gastroenterology 2004; 127 (Suppl 1): S17-26.
15. Fattovich G, Stroffelini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004; 127 (Suppl 1): S35-50.
16. Lagiou P, Kuper H, Stuver SO, Tzonou A, Trichopoulas D, Adami HO. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 2000; 92: 1096-9.
17. Hassan MM, Hwang LY, Hatten CJ etal. Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36: 1206-13.
18. El-Serag HB, Tran T, Everhart JE. Diabetes increase the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-8.
19. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: A population based case control study. Gut 2005; 54: 533-9.
20. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-38.
21. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 2004; 127 (Suppl 1): S97-103.
22. Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 2005; 23: 4742-54.
23. Moore MA, Park CB, Tsuda H. Implications of the hyperinsulinemia-diabetes-cancer link for preventive efforts. Eur J Cancer Prev 1998; 7: 89-107.
24. Balkau B, Kahn HS, Courbon D, Eschwege E, Ducimetiere P. Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites: The Paris Prospective Study. Diabetes Care 2001; 24: 843-9.